NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
NeOnc Technologies reported that a critically ill three-year-old boy treated with investigational intranasal NEO100 under a compassionate-use program coordinated with Abu Dhabi health authorities is breathing independently and beginning to move his legs. The company cautions a single-patient case cannot establish efficacy. NEO100's broader clinical benchmark remains August's 24-patient Phase 2a topline data showing 48.9% six-month progression-free survival and 26.09 months median overall survival. NEO212, an oral candidate, completed Phase 1 dose escalation with an FDA End-of-Phase 1 Type B meeting scheduled for November 17, 2026.
Key figures
- Drug Name
- NEO100
- Phase Of Trial
- Phase 2a
- Phase2a pfs 6mo
- 48.9%
- Fab total assets
- AED 1.41 trillion
- Phase2a patients
- 24
- Offering proceeds
- $15 million
- Fda type b meeting date
- 2026-11-17
- Phase2a median os months
- 26.09
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.